...
首页> 外文期刊>World Journal of Gastroenterology >Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B
【24h】

Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B

机译:丹酚酸B治疗慢性乙型肝炎肝纤维化的临床观察。

获取原文
获取原文并翻译 | 示例
           

摘要

CONCLUSION: SA-B could effectively reverse liver fibrosis in chronic hepatitis B. SA-B was better than IFN- γin reduction of serum HA content, overall decrease of 4 serum fibrotic markers, and decrease of ultrasound imaging score. Liver fibrosis in chronic hepatitis B with slight liver injury was more suitable to SA-B in anti- fibrotic treatment. SA-B showed no obvious side effects. AIM: To evaluate the clinical efficacy of salvianolic acid B (SA-B) on liver fibrosis in chronic hepatitis B. METHODS: Sixty patients with definite diagnosis of liver fibrosis with hepatitis B were included in the trial. Interferon-γ (IFN-γ) was used as control drug. The patients took orally SA-B tablets or received muscular injection of IFN-γ in the double blind randomized test.
机译:结论:SA-B可有效逆转慢性乙型肝炎的肝纤维化。SA-B在降低血清HA含量,降低4种血清纤维化标志物和降低超声影像学评分方面优于IFN-γ。慢性乙型肝炎伴轻度肝损伤的肝纤维化更适合SA-B进行抗纤维化治疗。 SA-B没有明显的副作用。目的:评价丹酚酸B(SA-B)对慢性乙型肝炎肝纤维化的临床疗效。方法:该试验包括60例明确诊断为乙型肝炎肝纤维化的患者。干扰素-γ(IFN-γ)用作对照药物。在双盲随机试验中,患者口服SA-B片剂或肌肉注射IFN-γ。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号